Date: 2012-09-11
Type of information: Grant
Company: Arsanis Biosciences (Austria)
Investors: Austrian Research Promotion Agency (Austria) - European Eurostars Programme (EU)
Amount: € 4.55 million
Funding type: grant
Planned used:
Others: Arsanis Biosciences GmbH, an early stage biotechnology company developing anti-infective human monoclonal antibodies, has been awarded a EUROSTARS grant with € 4.55 million - mainly funded by national agencies - The grant is awarded to the KLEBSICURE consortium with Arsanis as consortium leader, and GATC GmbH (Constance, Germany), the Max Planck Institute for Infectious Biology (Berlin, Germany) and the Ludwik Hirszfeld Institute of Immunology and Experimental Therapy (Wroclaw, Poland) as consortium members.
Therapeutic area: Infectious diseases
